The following is a summary of all of our potential new drugs that are currently in, or close to entering, clinical development. The chart also includes potential new indications for
VELCADE
®
(bortezomib) for Injection.
Click
here
for a
printable version
of this page.
COMMERCIAL PROGRAMS
PRECLINICAL
PHASE I
PHASE II
PHASE III
MARKET
O N C O L O G Y
VELCADE (multiple myeloma)
VELCADE (mantle cell lymphoma)
VELCADE (follicular/marg. zn.)
VELCADE (other tumors)
MLN0518 (AML)
MLN8054 (advanced malignancies)
MLN8237 (advanced malignancies)
MLN4924 (advanced malignancies)
MLN2238 (advanced malignancies)
I N F L A M M A T I O N
MLN0002 (UC, Crohn's)
MLN3126 (Crohn's)
MLN1202 (atherosclerosis)
MLN3897 / 3701 (inflammatory diseases)
MLN0415 (RA, MS, COPD, IBD)
MLN6095 (asthma, allergic rhinitis)
© 2008 Millennium Pharmaceuticals, Inc.
Update Notice
|
Usage Terms
|
Privacy Policy
COMMERCIAL PROGRAMS 